SEARCH NOTES

14 JUN 02

09/899,082

Databases searched: USPATFULL via EAST, Caplus, Medline, Biosis

Reviewed Parent Application(s): 09/378,900 and 09/044,665

Search terms:

Inventor(s): e.g. Maertens G?/au

STIC searched SEQ ID NOs: 1-4, 20 and 27

HCV

Hybridization

Amplification or PCR

Jos G-1

SEQ ID NO: 1

RESULT

I73300 LOCUS I73300 51 bp DNA linear PAT 03-APR-1998 DEFINITION Sequence 31 from patent US 5686272. ACCESSION I73300 I73300.1 GI:3009439 VERSION KEYWORDS SOURCE Unknown. Unknown. ORGANISM Unclassified. REFERENCE 1 (bases 1 to 51) Marshall, R.L., Carrino, J.J. and Sustachek, J.C. AUTHORS TITLE Amplification of RNA sequences using the ligase chain reaction Patent: US 5686272-A 31 11-NOV-1997; JOURNAL Location/Qualifiers FEATURES 1. .51 source /organism="unknown" BASE COUNT 14 a 16 c 11 t 10 g ORIGIN

```
Query Match 98.5%; Score 26.6; DB 6; Length 51; Best Local Similarity 96.3%; Pred. No. 0.036; Matches 26; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
```

```
SEQ ID NO: 1
RESULT 15
AAA75294
    AAA75294 standard; cDNA; 308 BP
TD
AC
     AAA75294;
DT
     15-JAN-2001
                 (first entry)
     Novel hepatitis C virus cDNA clone 18g.
DE
     Hepatitis C virus; HCV; antisense polynucleotide; polyprotein;
KW
     viral infectivity; viral replication; ds.
KW
ХX
OS
     Hepatitis C virus.
XX
PN
     EP1034785-A2.
ΧX
     13-SEP-2000.
PD
XX
     16-MAR-1990; 2000EP-0109602.
PF
XX
     17-MAR-1989;
                    89US-0325338.
PR
                    89US-0341334.
     20-APR-1989;
PR
PR
     18-MAY-1989;
                    89US-0355002.
PR
     16-MAR-1990;
                    90EP-0302866.
XX
     (CHIR ) CHIRON CORP.
PA
XX
     Houghton M, Choo Q,
                            Kuo G;
PΙ
XX
     WPI; 2000-566891/53.
DR
XX
     Novel composition comprising a hepatitis C virus antisense
PT
     polynucleotide which is complementary to or corresponds to a sense
PT
     strand of the virus genome, and selectively hybridises to it -
PT
XX
     Example; Fig 14; 75pp; English.
PS
XX
     The specification describes a pharmaceutical composition which
CC
     comprises a hepatitis C virus (HCV) antisense polynucleotide. The
CC
     HCV is characterized by a positive stranded RNA genome which has
CC
CC
```

The specification describes a pharmaceutical composition which comprises a hepatitis C virus (HCV) antisense polynucleotide. The HCV is characterized by a positive stranded RNA genome which has 40% homology at the polypeptide level to a HCV polyprotein. The antisense polynucleotide binds to cellular polynucleotides which enhance and/or are required for viral infectivity, replicative ability or chronicity. The antisense polynucleotides may also be designed to bind with high specificity, to be of increased stability, to be stable and to have low toxicity. The composition also comprises an agent which causes viral RNA to be inactive. The composition is used for preventing HCV replication in a system. The present sequence represents a novel HCV cDNA sequence, which is used in the course of the invention.

Sequence 308 BP; 59 A; 89 C; 94 G; 66 T; 0 other;

19 ccctgtgaggaactactgtcttcacgc 45

CC

CC

CC

CC

CC

CC

CC

CC

CC XX

SO

Dh

```
Query Match 98.5%; Score 26.6; DB 21; Length 308; Best Local Similarity 96.3%; Pred. No. 0.011; Matches 26; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1 CCCTGTGAGGAACTWCTGTCTTCACGC 27
```

```
SEQ ID NO: 1
RESULT
HPCBR56A
LOCUS
           HPCBR56A
                                    296 bp
                                              RNA
                                                      linear
                                                              VRL
03-FEB-1999
DEFINITION Hepatitis C virus RNA, 5'untranslated region.
ACCESSION
           D13448
VERSION
           D13448.1 GI:435625
            5' untranslated region.
KEYWORDS
            Hepatitis C virus (isolate: BR56) cDNA to genomic RNA.
SOURCE
  ORGANISM Hepatitis C virus
            Viruses; ssRNA positive-strand viruses, no DNA stage;
Flaviviridae;
           Hepacivirus.
REFERENCE
            2 (sites)
  AUTHORS
           Bukh, J., Purcell, R.H. and Miller, R.H.
            Sequence analysis of the 5' noncoding region of hepatitis C virus
  TITLE
            Proc. Natl. Acad. Sci. U.S.A. 89 (11), 4942-4946 (1992)
  JOURNAL
  MEDLINE
            92279243
FEATURES
                    Location/Qualifiers
     source
                    1. .296
                     /organism="Hepatitis C virus"
                     /isolate="BR56"
                    /db xref="taxon:11103"
                53 a 88 c 94 g
BASE COUNT
                                          61 t
ORIGIN
                         98.5%; Score 26.6; DB 14; Length 296; 96.3%; Pred. No. 0.027;
  Query Match
  Best Local Similarity
  Matches 26; Conservative 1; Mismatches 0; Indels
                                                               0; Gaps
0;
        1 CCCTGTGAGGAACTWCTGTCTTCACGC 27
Qу
```

The And

6 CCCTGTGAGGAACTTCTGTCTTCACGC 32

Db

```
SEQ ID NO: 2
RESULT
AA085918
ID
     AAQ85918 standard; DNA; 21 BP.
XX
AC
     AAQ85918;
XX
DT
     02-NOV-1995 (first entry)
XX
DE
     Hepatitis C virus genome external PCR primer YK-104.
XX
KW
     Hepatitis C virus; HCV; non-A non-B; external PCR primer;
KW
     YK-104; primer specific detection; ss.
XX
os
     Synthetic.
XX
PN
     WO9506753-A.
XX
PD
     09-MAR-1995.
XX
PF
     02-SEP-1994;
                    94WO-US09869.
XX
PR
     03-SEP-1993;
                    93US-0116344.
XX
     (USSH ) US DEPT HEALTH & HUMAN SERVICES.
PΑ
XX
ΡI
     Fields HA, Khudyakov YE;
XX
DR
     WPI; 1995-115465/15.
XX
PT
     New method and kit for primer-specific detection of nucleic acids
PT
      - using two primers having a known sequence and a marker, resp
PT
     for solid-phase detection of amplification prods.
XX
PS
     Example 1; Page 11; 20pp; English.
XX
     AAQ85918/19 are external, and AAQ85820/21 are internal PCR primers for
CC
CC
     the Hepatitis C virus (HCV) genome. They were used to demonstrate
CC
     a new method for the primer specific detection of nucleic acids.
XX
     Sequence 21 BP; 4 A; 6 C; 7 G; 4 T; 0 other;
SQ
                          100.0%; Score 21; DB 16; Length 21; 100.0%; Pred. No. 0.22;
  Query Match
  Best Local Similarity
  Matches
          21; Conservative
                               0; Mismatches
                                                 0; Indels
                                                                 0; Gaps
                                                                             0;
Qу
        1 GGTGCACGGTCTACGAGACCT 21
          Db
        1 ggtgcacggtctacgagacct 21
```

```
SEQ ID NO: 2
RESULT
AAQ67081
    AAQ67081 standard; DNA; 25 BP.
ID
XX
AC
    AAQ67081;
XX
DT
    14-MAR-1995 (first entry)
XX
    Antisense primer for amplifying Hepatitis C virus DNA fragment.
DE
XX
KW
    Hepatitis C virus; restriction endonuclease; KpnI; marker;
KW
     cleavage site; HCV; ss.
XX
OS
    Synthetic.
XX
PN
    JP06181764-A.
XX
PD
    05-JUL-1994.
XX
PF
     20-JAN-1993;
                   93JP-0007721.
XX
PR
     22-SEP-1992;
                   92JP-0252793.
XX
     (SAKA ) OTSUKA PHARM CO LTD.
PA
XX
    WPI; 1994-251687/31.
DR
XX
PT
     DNA contg. KPNI recognition site as marker for hepatitis C virus
PT
     - useful in diagnosis of HC
XX
PS
    Disclosure; Page 8; 9pp; Japanese.
XX
     Two primers (AAQ67080, AAQ67081) were used to amplify the sequence
CC
CC
     described in AAQ67079 which is obtained from hepatitis C virus (HCV)
CC
     and comprises a KpnI restriction endonuclease recognition site.
CC
     The restriction site is found in the wild type sequence and can
CC
     therefore be used as a diagnostic marker.
XX
SQ
     Sequence 25 BP; 5 A; 8 C; 7 G; 5 T; 0 other;
  Query Match
                         100.0%; Score 21; DB 15; Length 25;
  Best Local Similarity
                         100.0%; Pred. No. 0.22;
          21; Conservative 0; Mismatches 0; Indels 0; Gaps
                                                                           0;
Qу
        1 GGTGCACGGTCTACGAGACCT 21
          1111111111
Db
        3 ggtgcacggtctacgagacct 23
```

SEQ ID NO: 2

```
RESULT
US-08-441-971-33/c
; Sequence 33, Application US/08441971
; Patent No. 6071693
  GENERAL INFORMATION:
     APPLICANT: Tai-An Cha
     TITLE OF INVENTION: HCV GENOMIC SEQUENCES FOR
     TITLE OF INVENTION: DIAGNOSTICS AND THERAPEUTICS
     NUMBER OF SEQUENCES: 147
     CORRESPONDENCE ADDRESS:
       ADDRESSEE: Wolf, Greenfield & Sacks, P.C.
       STREET: 600 Atlantic Avenue
       CITY: Boston
       STATE: Massachusetts
       COUNTRY: USA
       ZIP: 02210
    COMPUTER READABLE FORM:
       MEDIUM TYPE: Diskette, 5.25 inch
       COMPUTER: IBM compatible
       OPERATING SYSTEM: MS-DOS Version 3.3
       SOFTWARE: WordPerfect 5.1
    CURRENT APPLICATION DATA:
      APPLICATION NUMBER: US/08/441,971
      FILING DATE: 16-MAY-1995
      CLASSIFICATION: 435
    PRIOR APPLICATION DATA:
      APPLICATION NUMBER: US/08/221,653
       FILING DATE:
      APPLICATION NUMBER: US/07/881,528
      FILING DATE:
      APPLICATION NUMBER: 07/697,326
      FILING DATE: 8 May 1991
    ATTORNEY/AGENT INFORMATION:
      NAME: Janiuk, Anthony J.
      REGISTRATION NUMBER: 29,809
      REFERENCE/DOCKET NUMBER: C0772/7000
    TELECOMMUNICATION INFORMATION:
      TELEPHONE: (617) 720-3500
      TELEFAX: (617) 720-2441
      TELEX: EZEKIEL
  INFORMATION FOR SEQ ID NO: 33:
    SEQUENCE CHARACTERISTICS:
      LENGTH: 252 nucleotides
      TYPE: nucleic acid
      STRANDEDNESS: single
      TOPOLOGY: linear
    MOLECULE TYPE: DNA
    ORIGINAL SOURCE: (ATCC # 40394)
       INDIVIDUAL ISOLATE: hcv1
US-08-441-971-33
 Query Match
                         100.0%; Score 21; DB 3; Length 252;
 Best Local Similarity 100.0%; Pred. No. 0.052;
           21; Conservative 0; Mismatches 0; Indels
                                                                         0;
Qу
       1 GGTGCACGGTCTACGAGACCT 21
         Db
     252 GGTGCACGGTCTACGAGACCT 232
```

```
SEQ ID NO: 2
RESULT
AAQ43112
ID
     AAQ43112 standard; DNA; 29 BP.
XX
AC
     AAQ43112;
XX
DT
     23-SEP-1993 (first entry)
XX
DE
    HCV 5'NCR antisense primer 209.
XX
KW
     Non-coding region; hepatitis C virus; blood donor; type 2; type 1;
KW
     HCV; NS-5; phylogeny; differentiation; NS-3; core region; type 3;
KW
     PCR; amplify; polymerase chain reaction; primer; NS4; ss.
XX
OS
     Synthetic.
XX
PN
     WO9310239-A.
XX
PD
     27-MAY-1993.
XX
PF
     20-NOV-1992;
                    92WO-GB02143.
XX
PR
     21-NOV-1991;
                    91GB-0024696.
PR
     24-JUN-1992;
                    92GB-0013362.
XX
PA
     (COMM-) COMMON SERVICES AGENCY.
XX
ΡI
     Chan S, Simmonds P, Yap PL;
XX
DR
     WPI; 1993-182554/22.
XX
PT
     DNA encoding antigenic peptide(s) of new types of hepatitis C
PT
     virus - for diagnosing and treating HCV infection, screening
PT
     blood samples and identifying different HCV types
XX
PS
     Disclosure; Page 27; 120pp; English.
XX
CC
     The sequences given in AAQ43112-33 are primers which were used to
CC
     amplify specific regions of the hepatitis C virus (HCV) genome.
CC
     Analysis of regions of the HCV genome revealed the existance of
     three distinct groups of HCV. Analysis of the region encompassing
CC
     -255 to -62 of the 5' non coding region (NCR) (see AAQ43058-75) showed
CC
CC
     a difference of 9-14% in the nucleotide sequences between the three
CC
     groups. Two of the groups identified were similar to those of HCV
CC
     varients termed type 1 and 2, whilst the third appeared to represent
CC
     a novel type of virus. Comparison of the NS3 region (see AAR37927-30)
     showed a high degree of sequence diversity with type 3 being phylo-
CC
CC
     genetically different to type 1 and 2. The same degree different-
     iation was noted in the NS-5 (see AAR37923-26), core region (see
CC
CC
     AAR37931) and the NS4 region (see AAQ43106-111) between type 3 and type
CC
     1 sequences.
XX
     Sequence 29 BP; 7 A; 8 C; 8 G; 6 T; 0 other;
SQ
                          100.0%; Score 21; DB 14; Length 29; 100.0%; Pred. No. 0.22;
  Query Match
  Best Local Similarity
 Matches
           21; Conservative
                               0; Mismatches
                                                  0; Indels
                                                               0; Gaps
                                                                             0;
        1 GGTGCACGGTCTACGAGACCT 21
Qу
          Db
        9 ggtgcacggtctacgagacct 29
```